Research Use Only. Not for human or veterinary use. Not medical advice.

RC-CJCIPA · Endocrine Signaling Research

RC-CJCIPA vial (catalog image)

RC-CJCIPA

Endocrine Signaling Research

Catalog code Research material Multi-constituent blend 10 mg vial
Presentation

Vial sizes for laboratory supply, not a protocol.

Pricing
Sign in
Researcher pricing for approved accounts
In stock
As listed on the public catalog, Nov 17, 2026
Add to cart
0 25 50 75
77 of 100

Popularity

High

Public interest index

Trending level+4% vs prior 30 days

Research: Literature Activity not scored (blend)

Data as of Nov 17, 2026 · Sources: Wikipedia pageviews, Reddit, X public mentions.

Measures online attention only. It is not a measure of quality, purity, efficacy, or safety.

Publications per year

This catalog item is a multi-constituent blend, so there is no honest single-compound PubMed corpus and no publications-per-year chart. Literature Activity is not scored.

The cards in Research Literature describe published studies of the named constituents CJC-1295 and ipamorelin. They are not trials of this finished blend. A named-compound search for CJC-1295 OR CJC1295 returned 35 unique records on Nov 17, 2026; ipamorelin returned 55. Those totals are not used as a blend score.

Key specifications

Catalog facts are taken from the live PEPTIDEA™ listing. Formula and molecular weight are from PubChem. Sequence is omitted here.

Catalog title
RC-CJCIPA | Endocrine Signaling Research
Research focus
Endocrine Signaling Research
Also described as
CJC-1295 and ipamorelin (multi-constituent research blend)
Format
Lyophilized research peptide blend
Catalog status
In stock (public listing)
Presentations
10 mg vialCatalog sizes, not a protocol
Molecular formula
Blend — see catalog notesNot a single compound; no blend PubChem CID
Molecular weight
Not a single formulaMulti-constituent blend
Receptor context
Not applicable as a single ligand — named constituents are described separately as a GHRH analog and a ghrelin-receptor agonistCatalog identity and constituent literature; research context only
Sequence
Not reproduced hereSee primary literature / PubChem
Researcher access
Sign-in required to view pricing

Catalog notes & use limitations

Research-catalog framing only. This section does not describe effects in people or study outcomes.

Catalog notes

Listed under Endocrine Signaling Research

RC-CJCIPA appears in the PEPTIDEA™ Endocrine & Growth Factor Signaling Research collection with the single-compound ipamorelin listing RC-IPA and with RC-TESA.

Multi-constituent blend; DAC form not specified

Handbook notes identify the constituents as CJC-1295 and ipamorelin. The catalog does not state whether the CJC component is the DAC form or Modified GRF (1-29). Those two CJC-1295-named materials are not interchangeable, and this page does not assign one of them to the vial.

No blend-level PubMed corpus

Literature cards below are studies of the named constituents. They are not clinical or laboratory trials of this finished blend.

10 mg vial

The catalog presentation is a 10 mg vial (SKU RC-104-10). The constituent ratio is not stated on this page, and this page does not assign a CJC form (DAC or Modified GRF (1-29)) to the vial. This is a presentation of the research material, not a protocol.

Use limitations

Research use only

Not for human or veterinary use. Not a drug, not a cosmetic, and not medical advice. Not presented here as a treatment or weight-management product.

No outcome or dosing information

This page does not list administration amounts, schedules, or clinical results. Catalog vial sizes are presentations of the research material, not a protocol.

Confirm details from primary sources

Formula and molecular weight are cited from PubChem when a single compound applies; otherwise see the catalog notes. Sequence is omitted. Read the original papers for laboratory context — results stay in the original publications.

Specifications

Laboratory-catalog and public-chemistry details. Items without a cited source are marked.

Catalog titleRC-CJCIPA | Endocrine Signaling Research
CategoryEndocrine Signaling Research (Endocrine & Growth Factor Signaling Research)
Associated namesMulti-constituent blend; not a single compound
FormatLyophilized research peptide blend
Public catalog statusIn stock (as of Nov 17, 2026)
Catalog presentations10 mg vial — sizes of the research material, not a use protocol
Molecular formulaBlend — see catalog notes (Not a single compound; no blend PubChem CID, retrieved Nov 17, 2026)
Molecular weightNot a single formula (Multi-constituent blend)
InChIKeyNot applicable (PubChem)
Receptor contextInternal handbook notes identify this listing as a CJC-1295 and ipamorelin blend. The public catalog does not specify whether the CJC component is the Drug Affinity Complex (DAC) form or Modified GRF (1-29) / CJC-1295 without DAC. This page does not choose between those forms.
SequenceNot reproduced on this page. See primary literature and the PubChem record.
PricingVisible after researcher sign-in
There is no single PubChem record for the finished blend. A CID for one CJC-1295 form is not cited as the formula of this product.

Research literature

These are Peptidea-written summaries of selected publications, prepared so you can stay on peptidea.net. Each card describes what was studied — the research question, study type, and mechanism or setting. We do not restate results, endpoints, or protocols. Full papers remain with their publishers; a small PubMed source link is included only for citation.

Clinical pharmacology — constituent (CJC-1295), not the blend

Teichman et al.

The Journal of Clinical Endocrinology & Metabolism · 2006
The albumin-binding DAC form of CJC-1295, a long-acting GHRH analog, and GH / IGF-1 measurements in adults

This paper examined the albumin-binding DAC form of CJC-1295, described as a long-acting analog of growth hormone-releasing hormone, with measurements of growth hormone and insulin-like growth factor I secretion. It is included because CJC-1295 is a named constituent of this blend, not because the paper studied the blend, and it does not identify which CJC form is in the catalog vial.

Hormone-response values, duration findings, and administration amounts in the paper are not restated on this page.

Clinical pharmacology — constituent (CJC-1295), not the blend

Ionescu and Frohman

The Journal of Clinical Endocrinology & Metabolism · 2006
Pulsatile growth-hormone measurements during exposure to the DAC form of CJC-1295

This paper studied pulsatile growth-hormone secretion during exposure to the albumin-binding DAC form of CJC-1295, described as a long-acting growth hormone-releasing hormone analog. It is included because CJC-1295 is a named constituent of this blend, not because the paper studied the blend, and it does not identify which CJC form is in the catalog vial.

Secretion-pattern findings and any other results in the paper are not reproduced here.

Experimental, animal model — constituent chemistry (GHRH analog / albumin bioconjugate), not the blend

Jetté et al.

Endocrinology · 2005
Human GRF (1–29)–albumin bioconjugates and the GRF receptor in rats

This paper examined human growth hormone-releasing factor (1–29)–albumin bioconjugates and their activity at the GRF receptor in rats, work that is part of the published DAC / long-acting GHRH-analog chemistry. It is included as constituent-context literature, not as a study of this finished blend, and it does not identify which CJC form is in the catalog vial.

Receptor-activity findings and conjugate-design results in the paper are not restated here.

Preclinical pharmacology — constituent (ipamorelin), not the blend

Raun et al.

European Journal of Endocrinology · 1998
Description of ipamorelin as a growth-hormone secretagogue

This paper introduces ipamorelin as a synthetic pentapeptide growth-hormone secretagogue and reports in-vitro and in-vivo pharmacology. It is included because ipamorelin is a named constituent of this blend, not because the paper studied the blend.

Potency, selectivity, and other experimental results in the paper are not restated on this page.

Clinical pharmacology, healthy volunteers — constituent (ipamorelin), not the blend

Gobburu et al.

Pharmaceutical Research · 1999
Pharmacokinetic–pharmacodynamic study of ipamorelin in healthy volunteers

This paper reports pharmacokinetic and pharmacodynamic modeling of ipamorelin in healthy volunteers. It is included because ipamorelin is a named constituent of this blend, not because the paper studied the blend.

Infusion rates, pharmacokinetic parameters, and growth-hormone response values in the paper are not reproduced here.

Storage & handling

General laboratory-catalog guidance for layout purposes. Always follow the vial label and your institution’s written procedures.

  • Handle as a lyophilized research material intended for laboratory use only.
  • Store according to the conditions printed on the label and in any compound document provided to approved researchers.
  • Protect closed vials from moisture and unnecessary temperature swings.
  • If reconstitution is performed, use only the laboratory’s own written procedures. This page does not provide volumes, solvents, or working concentrations.
  • This material is not for human or veterinary use and is not medical advice.
No dosing, administration, or protocol instructions are included on this page.

Research Use Only. Not for human or veterinary use. Not medical advice. PEPTIDEA™ is a trademark of Grey Bug LLC.